Skip to Content

Trazec

Active Substance: nateglinide
Common Name: nateglinide
ATC Code: A10BX03
Marketing Authorisation Holder: Novartis Europharm Ltd.
Active Substance: nateglinide
Status: Withdrawn
Authorisation Date: 2001-04-03
Therapeutic Area: Diabetes Mellitus, Type 2
Pharmacotherapeutic Group: Drugs used in diabetes

Therapeutic Indication

Nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.

The marketing authorisation for Trazec has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide